Literature DB >> 6681869

Sclerosteosis: neurogenetic and pathophysiologic analysis of an American kinship.

S A Stein, C Witkop, S Hill, M D Fallon, L Viernstein, G Gucer, P McKeever, D Long, J Altman, N R Miller, S L Teitelbaum, S Schlesinger.   

Abstract

We studied an American kinship with sclerosteosis, an autosomal-recessive disorder of bone remodeling and bone overgrowth of the calvaria, skull base, and tubular bones. Unlike osteopetrosis, which is attributed to abnormal immune and osteoclast function as well as bone resorption, sclerosteosis appears to be primarily a disorder of osteoblast (bone formation) hyperactivity. Related to cranial vascular and neural foraminal narrowing and reduced intracranial volume, affected patients with sclerosteosis demonstrate frequent seventh nerve palsy, progressive optic and cranial neuropathies, mixed hearing loss, brainstem compression, intracranial hypertension with increased elastance, and sudden, premature death. Management should involve early childhood identification of homozygotes, monitoring and aggressive treatment of intracranial hypertension, and extensive bone removal from skull, posterior fossa, and cervical spine.

Entities:  

Mesh:

Year:  1983        PMID: 6681869     DOI: 10.1212/wnl.33.3.267

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  19 in total

1.  Osteocyte control of bone formation via sclerostin, a novel BMP antagonist.

Authors:  David G Winkler; May Kung Sutherland; James C Geoghegan; Changpu Yu; Trenton Hayes; John E Skonier; Diana Shpektor; Mechtild Jonas; Brian R Kovacevich; Karen Staehling-Hampton; Mark Appleby; Mary E Brunkow; John A Latham
Journal:  EMBO J       Date:  2003-12-01       Impact factor: 11.598

Review 2.  Sclerosing bone dysplasias--a target-site approach.

Authors:  A Greenspan
Journal:  Skeletal Radiol       Date:  1991       Impact factor: 2.199

Review 3.  TGF-β Family Signaling in Connective Tissue and Skeletal Diseases.

Authors:  Elena Gallo MacFarlane; Julia Haupt; Harry C Dietz; Eileen M Shore
Journal:  Cold Spring Harb Perspect Biol       Date:  2017-11-01       Impact factor: 10.005

Review 4.  Craniotubular bone disorders.

Authors:  R J Gorlin
Journal:  Pediatr Radiol       Date:  1994

5.  Localization of the gene for sclerosteosis to the van Buchem disease-gene region on chromosome 17q12-q21.

Authors:  W Balemans; J Van Den Ende; A Freire Paes-Alves; F G Dikkers; P J Willems; F Vanhoenacker; N de Almeida-Melo; C F Alves; C A Stratakis; S C Hill; W Van Hul
Journal:  Am J Hum Genet       Date:  1999-06       Impact factor: 11.025

Review 6.  Sclerostin: therapeutic horizons based upon its actions.

Authors:  Aline G Costa; John P Bilezikian
Journal:  Curr Osteoporos Rep       Date:  2012-03       Impact factor: 5.096

7.  Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women.

Authors:  Faryal S Mirza; I Desmond Padhi; Lawrence G Raisz; Joseph A Lorenzo
Journal:  J Clin Endocrinol Metab       Date:  2010-02-15       Impact factor: 5.958

8.  Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein.

Authors:  M E Brunkow; J C Gardner; J Van Ness; B W Paeper; B R Kovacevich; S Proll; J E Skonier; L Zhao; P J Sabo; Y Fu; R S Alisch; L Gillett; T Colbert; P Tacconi; D Galas; H Hamersma; P Beighton; J Mulligan
Journal:  Am J Hum Genet       Date:  2001-02-09       Impact factor: 11.025

9.  Polymorphisms in the sclerosteosis/van Buchem disease gene (SOST) region are associated with bone-mineral density in elderly whites.

Authors:  Andre G Uitterlinden; Pascal P Arp; Bryan W Paeper; Patrick Charmley; Sean Proll; Fernando Rivadeneira; Yue Fang; Joyce B J van Meurs; Theresa B Britschgi; John A Latham; Randall C Schatzman; Huibert A P Pols; Mary E Brunkow
Journal:  Am J Hum Genet       Date:  2004-10-26       Impact factor: 11.025

10.  Sclerosteosis in a Spanish male: first report in a person of Mediterranean origin.

Authors:  M Bueno; G Oliván; A Jiménez; J M Garagorri; A Sarría; A L Bueno; M Bueno; F J Ramos
Journal:  J Med Genet       Date:  1994-12       Impact factor: 6.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.